The iPLEDGE REMS system has previously been associated with disparities in isotretinoin access by sex and race, but the racial impact of the 2021 system update remains unclear. We conducted a retrospective cohort study of patients prescribed isotretinoin at an urban academic center between 2018 and 2023, evaluating iPLEDGE-related medication delays and interruptions using interrupted time series analyses stratified by race. Following the December 2021 update, iPLEDGE-related delays increased significantly among Asian and Black patients, with no significant change among White patients. Black patients also experienced increased treatment interruptions. Given the single-center design and sample size limitations, further multicenter studies are needed to assess generalizability and fully characterize racial disparities in isotretinoin access.
No takes yet. Share an insight, caveat, or question.
Beagles et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: